Loading institutional data...
Loading institutional data...
Held by 279 of 5,944 reporting institutions (94th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $673.0M 100.0% | $560.0M 100.0% | $434.0M 100.0% | $363.3M 100.0% | $351.4M 100.0% | $271.0M 100.0% | $103.7M 100.0% | $51.5M 100.0% | $2.6M 100.0% | $133K 100.0% |
| Cost of Revenue | — | — | — | — | — | — | — | $1.1M 2.2% | $1K 0.0% | — |
| Cost of Products | — | — | — | — | — | — | — | — | $1K 0.0% | — |
| Research & Development | $750.0M 111.4% | $698.0M 124.6% | $648.0M 149.3% | $705.8M 194.3% | $497.2M 141.5% | $412.1M 152.0% | $357.4M 344.6% | $294.0M 570.9% | $231.6M 8868.5% | $183.2M 137747.4% |
| Selling, General & Admin | $349.0M 51.9% | $321.0M 57.3% | $310.0M 71.4% | $278.1M 76.6% | $220.0M 62.6% | $182.9M 67.5% | $161.5M 155.7% | $127.7M 248.0% | $99.9M 3825.0% | $64.9M 48824.1% |
| Total Operating Expenses | — | — | — | — | — | $601.1M 221.8% | $527.9M 509.0% | $422.9M 821.2% | $331.6M 12693.5% | $248.1M 186571.4% |
| Operating Income | -$535.0M -79.5% | -$536.0M -95.7% | -$569.0M -131.1% | -$648.9M -178.6% | -$381.7M -108.6% | -$330.1M -121.8% | -$424.2M -409.0% | -$371.4M -721.2% | -$328.9M -12593.5% | -$248.0M -186471.4% |
| Interest & Investment Income | $25.0M 3.7% | $37.0M 6.6% | $27.0M 6.2% | $11.1M 3.0% | $1.9M 0.5% | $7.0M 2.6% | $13.2M 12.8% | $9.5M 18.5% | $4.1M 156.0% | $3.8M 2848.9% |
| Other Income (Expense), net | $1.0M 0.1% | -$5.0M -0.9% | -$1.0M -0.2% | -$1.6M -0.4% | -$1.7M -0.5% | $607K 0.2% | -$787K -0.8% | -$5.6M -10.9% | $6.5M 250.0% | $2.2M 1630.1% |
| Pretax Income | -$571.0M -84.8% | -$567.0M -101.3% | -$609.0M -140.3% | -$701.7M -193.1% | -$453.0M -128.9% | -$185.4M -68.4% | -$399.4M -385.1% | -$197.1M -382.7% | -$318.3M -12187.5% | -$245.8M -184841.4% |
| Income Tax Expense | $4.0M 0.6% | $2.0M 0.4% | -$2.0M -0.5% | $5.7M 1.6% | $1.0M 0.3% | $1.2M 0.4% | $3.3M 3.2% | $514K 1.0% | -$16.2M -620.2% | $35K 26.3% |
| Net Income | -$575.0M -85.4% | -$569.0M -101.6% | -$607.0M -139.9% | -$707.4M -194.7% | -$454.0M -129.2% | -$186.6M -68.8% | -$402.7M -388.3% | -$197.6M -383.7% | -$302.1M -11567.3% | -$245.9M -184867.7% |
| Per Share | ||||||||||
| EPS (Basic) | $-5.83 | $-6.29 | $-8.25 | $-10.12 | $-6.70 | $-3.07 | — | — | — | — |
| EPS (Diluted) | $-5.83 | $-6.29 | $-8.25 | $-10.12 | $-6.70 | $-3.07 | — | — | — | — |
| Weighted Avg Shares (Basic) | 98.6M | 90.5M | 73.5M | 69.9M | 67.8M | 60.8M | — | — | — | — |
| Weighted Avg Shares (Diluted) | 98.6M | 90.5M | 73.5M | 69.9M | 67.8M | 60.8M | — | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
4/7 of the 9 checks — 2 couldn't be scored (see above), so the score is out of the 7 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$472M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: 719%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
Where each multiple sits in its own 12-yr range · 0th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 12-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 2.2 | — | — | — | — | — | — | — |
| R&D | 570.9 | 344.6 | 152.0 | 141.5 | 194.3 | 149.3 | 124.6 | 111.4 |
| SG&A | 248.0 | 155.7 | 67.5 | 62.6 | 76.6 | 71.4 | 57.3 | 51.9 |
| Operating Income | -721.2 | -409.0 | -121.8 | -108.6 | -178.6 | -131.1 | -95.7 | -79.5 |
| Income Tax | 1.0 | 3.2 | 0.4 | 0.3 | 1.6 | -0.5 | 0.4 | 0.6 |
| Net Income | -383.7 | -388.3 | -68.8 | -129.2 | -194.7 | -139.9 | -101.6 | -85.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on RARE: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| RARE | $1.4B | — | — | 2.1× | 20.2% | — | -85.4% | 719% | 719% | — | 279 |
Peers = companies sharing RARE's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.